Nanoform Q2 report: All business targets for 2024 on track
Company Announcement Nanoform Finland Plc August 29, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q2 report: All business targets for 2024 on track Manufacturing of GMP material in project nanoenzalutamide continues. One or several license/commercial supply agreements are expected to be signed during 2024. Our product kernel build-out progresses well. Fimea approved our new GMP QC laboratory. A preclinical development agreement was announced with Takeda. After a burst of signings in early 3Q, including multi-API non-GMP deals with both a new and an existing